Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415864 | 0.89 | MAPT (0.53) | TRPV1MAPTTP53KDRLMNA | |
| SCHEMBL12415805 | 0.89 | MAPT (0.52) | MAPTTHRBKDRLMNAGAA | |
| SCHEMBL12415866 | 0.88 | MAPT (0.49) | MAPTTP53KDRLMNARXFP1 | |
| SCHEMBL12415881 | 0.87 | PANK3 (0.53) | TRPV1MAPTTP53LMNARXFP1 | |
| SCHEMBL12415863 | 0.87 | TP53 (0.62) | MAPTTP53THRBKDRGAA | |
| SCHEMBL12415900 | 0.87 | MAPT (0.48) | MAPTTP53THRBKDRLMNA | |
| SCHEMBL12415875 | 0.85 | MAPT (0.54) | MAPTKDRLMNAGAARXFP1 | |
| SCHEMBL12415878 | 0.85 | TP53 (0.50) | TRPV1MAPTTP53THRBKDR | |
| SCHEMBL12415883 | 0.85 | MAPT (0.49) | TRPV1MAPTTP53THRBKDR | |
| SCHEMBL12415872 | 0.84 | NPSR1 (0.53) | TRPV1MAPTTP53KDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R3, AKT3, AKT2 | TRPV1 3967/4885MAPT 2999/4885TP53 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.